{"id":"intravenous-diltiazem","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Hypotension"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"3-5","effect":"Dizziness"},{"rate":"2-4","effect":"Headache"},{"rate":"2-3","effect":"Flushing"},{"rate":"2-3","effect":"Asthenia/fatigue"},{"rate":"1-2","effect":"Atrioventricular block"}]},"_chembl":{"chemblId":"CHEMBL1200805","moleculeType":"Small molecule","molecularWeight":"548.61"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Diltiazem blocks L-type calcium channels in the sinoatrial and atrioventricular nodes, slowing conduction velocity and increasing refractoriness. This results in negative chronotropic and dromotropic effects, reducing heart rate and contractility while also causing vasodilation of coronary and peripheral arteries. The intravenous formulation provides rapid onset for acute management of supraventricular arrhythmias and hypertensive episodes.","oneSentence":"Diltiazem is a non-dihydropyridine calcium channel blocker that inhibits calcium influx into cardiac and vascular smooth muscle cells, reducing heart rate and blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:45.267Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Supraventricular tachycardia (acute management)"},{"name":"Atrial fibrillation with rapid ventricular response (acute management)"},{"name":"Hypertensive crisis"}]},"trialDetails":[{"nctId":"NCT07456423","phase":"PHASE4","title":"Adenosine vs. Diltiazem","status":"COMPLETED","sponsor":"Haseki Training and Research Hospital","startDate":"2024-07-01","conditions":"Supraventricular Tachycardia (SVT), Atrioventricular Nodal Re Entrant Tachycardia","enrollment":140},{"nctId":"NCT07445334","phase":"NA","title":"Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes","status":"NOT_YET_RECRUITING","sponsor":"Western Sydney Local Health District","startDate":"2026-03-01","conditions":"Premature Ventricular Complexes, Premature Ventricular Contraction (PVC), Premature Ventricular Beats","enrollment":40},{"nctId":"NCT06276127","phase":"PHASE3","title":"Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter With Rapid Ventricular Rate.","status":"NOT_YET_RECRUITING","sponsor":"Oman Medical Speciality Board","startDate":"2025-04","conditions":"Atrial Fibrillation With Rapid Ventricular Response, Atrial Flutter With Rapid Ventricular Response","enrollment":60},{"nctId":"NCT05391893","phase":"PHASE4","title":"Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation","status":"COMPLETED","sponsor":"Corewell Health South","startDate":"2020-06-19","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":444},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT05950971","phase":"NA","title":"Rhythm Control Versus Rate Control for New Onset Atrial Fibrillation","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2021-07-01","conditions":"Atrial Fibrillation New Onset, Atrial Fibrillation Paroxysmal","enrollment":1},{"nctId":"NCT03472495","phase":"PHASE4","title":"Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2018-06-01","conditions":"Atrial Fibrillation and Flutter","enrollment":19},{"nctId":"NCT05691959","phase":"PHASE2","title":"Pre-diltiazem, Calcium Versus Placebo for Atrial Fibrillation With Rapid Ventricular Response","status":"UNKNOWN","sponsor":"Ascension Health","startDate":"2023-01-26","conditions":"Atrial Fibrillation With Rapid Ventricular Response, Hypotension","enrollment":378},{"nctId":"NCT04234477","phase":"PHASE4","title":"Assessment of Intravenous Rate Control Response in Atrial Fibrillation Trial (AIRCRAFT)","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2021-12","conditions":"Atrial Fibrillation","enrollment":""},{"nctId":"NCT04141553","phase":"PHASE4","title":"Bolus vs IVP (Intravenous Push) Diltiazem for Atrial Fibrillation or Flutter","status":"UNKNOWN","sponsor":"Mercy Health Muskegon","startDate":"2019-12-01","conditions":"Atrial Fibrillation, Atrial Flutter, Rapid Ventricular Response","enrollment":300},{"nctId":"NCT03580590","phase":"EARLY_PHASE1","title":"Efficacy of Oral Diltiazem on the Intraoperative Bleeding in Functional Endoscopic Sinus Surgery","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-09-01","conditions":"Hypotension on Induction","enrollment":40},{"nctId":"NCT03529149","phase":"PHASE4","title":"TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT","status":"UNKNOWN","sponsor":"Xuanwu Hospital, Beijing","startDate":"2018-04-08","conditions":"Acute Ischemic Stroke","enrollment":90},{"nctId":"NCT02025465","phase":"PHASE4","title":"Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control","status":"UNKNOWN","sponsor":"CAMC Health System","startDate":"2013-12","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":150},{"nctId":"NCT01176565","phase":"PHASE3","title":"Antihypertensive Treatment of Acute Cerebral Hemorrhage-II","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2011-05-15","conditions":"Intracerebral Hemorrhage","enrollment":1000},{"nctId":"NCT00413712","phase":"PHASE4","title":"Effectiveness of Calcium Channel Blockers and Adenosine in the Emergency Management of SVT","status":"COMPLETED","sponsor":"Singapore General Hospital","startDate":"1997-01","conditions":"Supraventricular Tachycardia","enrollment":206},{"nctId":"NCT02308748","phase":"PHASE1","title":"Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2014-05","conditions":"Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics","enrollment":22},{"nctId":"NCT00803634","phase":"PHASE3","title":"Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2008-12","conditions":"Hypertension, Heart Failure","enrollment":117},{"nctId":"NCT01279499","phase":"PHASE2, PHASE3","title":"Sevoflurane Versus Intravenous Anaesthetic Agents in Morbid Obese Patients","status":"UNKNOWN","sponsor":"University of Patras","startDate":"2010-04","conditions":"Morbid Obesity","enrollment":100},{"nctId":"NCT01124760","phase":"PHASE1","title":"Open Label Study, Assessing the Effect of Diltiazem or Ketoconazole on the Pharmacokinetics of AZD9742 in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2010-05","conditions":"Pharmacokinetics","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":197,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Diltiazem nondihydropyridine calcium channel blocker"],"phase":"phase_3","status":"active","brandName":"Intravenous Diltiazem","genericName":"Intravenous Diltiazem","companyName":"Oman Medical Speciality Board","companyId":"oman-medical-speciality-board","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous Diltiazem is a small molecule that acts as a voltage-gated L-type calcium channel blocker. It has been studied in various clinical trials for conditions such as morbid obesity, atrial fibrillation and flutter, acute ischemic stroke, hypotension on induction, and atrial fibrillation new onset.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}